<SEC-DOCUMENT>0001193125-20-197411.txt : 20200723
<SEC-HEADER>0001193125-20-197411.hdr.sgml : 20200723
<ACCEPTANCE-DATETIME>20200723060729
ACCESSION NUMBER:		0001193125-20-197411
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200723
FILED AS OF DATE:		20200723
DATE AS OF CHANGE:		20200723

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioNTech SE
		CENTRAL INDEX KEY:			0001776985
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			2M
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39081
		FILM NUMBER:		201042659

	BUSINESS ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
		BUSINESS PHONE:		0049613190847081

	MAIL ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d80965d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">6-K</FONT> </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE MONTH OF JULY 2020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>COMMISSION FILE NUMBER <FONT STYLE="white-space:nowrap">001-39081</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>BioNTech SE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Translation
of registrant&#146;s name into English) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>An der Goldgrube 12 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">D-55131</FONT> Mainz </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>Germany </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>+49 <FONT
STYLE="white-space:nowrap">6131-9084-0</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Address of principal executive office) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Form 40-F: Form 20-F &#9746; Form 40-F &#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Indicate by
check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>DOCUMENTS INCLUDED AS PART OF THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:10%; font-size:11pt; font-family:Times New Roman">On July&nbsp;22, 2020, BioNTech SE (the &#147;Company&#148;) issued a press release announcing the pricing of a public offering of
American Depositary Shares (&#147;ADSs&#148;) and the terms of a rights offering of rights to subscribe for ADSs and ordinary shares of the Company. A copy of the press release is attached hereto as Exhibit 99.1. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:10%; font-size:11pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"><B>BioNTech SE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top">&nbsp;&nbsp;By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:11pt; font-family:Times New Roman">/s/ Dr.&nbsp;Sierk Poetting</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Dr.&nbsp;Sierk Poetting</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Financial Officer and Chief Operating Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman">Date: July&nbsp;23, 2020 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:11pt; font-family:Times New Roman; " ALIGN="center">Exhibit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:11pt; font-family:Times New Roman; ">Description of Exhibit</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated<B> </B>July&nbsp;22, 2020 - BioNTech Announces Pricing of Upsized Underwritten Offering and Terms of Rights Offering</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d80965dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g80965dsp1.gif" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>BioNTech Announces Pricing of Upsized Underwritten Offering and Terms of Rights Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">July&nbsp;22, 2020 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">MAINZ, Germany, July&nbsp;22, 2020 (GLOBE NEWSWIRE) &#151;
BioNTech SE (Nasdaq: BNTX, &#147;BioNTech&#148; or &#147;the Company&#148;) announced today the pricing of its previously announced underwritten offering and terms of its previously announced rights offering. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">BioNTech announced the pricing of a firm commitment underwritten offering (the &#147;Underwritten Offering&#148;) of
5,500,000 American Depositary Shares (&#147;ADSs&#148;), each representing one of its ordinary shares, at a public offering price of $93.00 per ADS, for gross proceeds of $511.5&nbsp;million. The size of the offering was increased from the
previously announced offering size of 5,000,000 ADSs. For stabilization purposes, in connection with the Underwritten Offering, an existing shareholder has granted the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase
up to 825,000 additional ADSs at the same public offering price. BioNTech will not receive any of the proceeds from the sale of ADSs by the selling shareholder. The Underwritten Offering is expected to close on July&nbsp;27, 2020, subject to the
satisfaction of customary closing conditions. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">BioNTech announced the terms of a rights offering (the &#147;Rights Offering&#148;) of rights to subscribe for up to
7,505,596 ordinary shares, including ordinary shares represented by ADSs, extended to holders of its ordinary shares and ADSs. Certain ordinary shareholders representing 74.83% of the Company&#146;s outstanding ordinary shares have irrevocably
agreed not to transfer or exercise their rights in this offering, and the shares underlying those rights are being offered in the Underwritten Offering. ADSs purchased in the Underwritten Offering will not be entitled to receive rights in the Rights
Offering. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">Pursuant to the rights offering, holders of ADSs will receive one ADS right for each ADS owned of record as of 5:00 p.m.
(New York City time) on July&nbsp;24, 2020 and holders of ordinary shares will receive one ordinary share right for each ordinary share owned of record as of one minute after 11:59 p.m (Mainz, Germany time) on July&nbsp;29, 2020. 31 ADS rights will
entitle a holder of such rights to subscribe for and purchase one new ADS, at a subscription price of $93.00 per new ADS. 31 ordinary share rights will entitle a holder of such rights to subscribe for and purchase one new ordinary share, at a
subscription price of <FONT STYLE="font-family:Times New Roman">&#128;</FONT>80.32 per new ordinary share, which is the Euro equivalent of the U.S. dollar price per new ADS, translated based on the exchange rate in effect as of July&nbsp;22, 2020,
or $93.00 per new ordinary share. No fractional ADSs or ordinary shares will be issued. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9pt">The ADS rights exercise period is from 12:01 a.m. (New York City time) on July&nbsp;28, 2020 through 12:01 a.m. (New York
City time) on August&nbsp;14, 2020. The ordinary share rights exercise period is from one minute before 12:01 a.m. (Mainz, Germany time) on July&nbsp;28, 2020 through one minute after 11:59 p.m. (Mainz, Germany time) on August&nbsp;14, 2020. Rights
to purchase ADSs are not transferable and all exercises of ADS rights are irrevocable. ADS rights and ordinary share rights that are not exercised within the applicable period will expire and have not further value. Delivery of the ordinary shares
and the ADSs in the Rights Offering is expected to be made on or about August&nbsp;27, 2020. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="justify">J.P. Morgan, BofA Securities and
Berenberg are acting as lead joint book-running managers for the Underwritten Offering and as joint dealer-managers and subscription agents for the Rights Offering. UBS Investment Bank is acting as joint book-running manager and Canaccord Genuity is
acting as lead manager for the Underwritten Offering. COMMERZBANK, Wolfe Capital Markets and Advisory and Bryan, Garnier&nbsp;&amp; Co. are acting as <FONT STYLE="white-space:nowrap">co-managers</FONT> for the Underwritten Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="justify">A registration statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> relating to the securities offered in the Underwritten Offering has been
filed with the United States Securities and Exchange Commission (the &#147;SEC&#148;) and was declared effective on July&nbsp;22, 2020. A registration statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> relating to the securities offered
in the Rights Offering has been filed with the SEC but has not yet become effective. The securities offered in the Rights Offering may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="justify">The Underwritten Offering and the Rights Offering will each be made only by means of a prospectus, copies of which may be obtained, when available, for
free by visiting EDGAR on the SEC&#146;s website at www.sec.gov. Alternatively, copies of the prospectuses, when available, may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, New York 11717, or by telephone at +1 (866) <FONT STYLE="white-space:nowrap">803-9204,</FONT> or by <FONT STYLE="white-space:nowrap">e-mail</FONT> at <FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#0000ff"><U><FONT
STYLE="white-space:nowrap">prospectus-eq_fi@jpmchase.com</FONT></U></FONT><FONT STYLE="font-family:ARIAL">; BofA Securities, Inc.,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NC1-004-03-43;</FONT></FONT></FONT> 200 North College Street, 3rd Floor, Charlotte, North Carolina 28255-0001, Attention: Prospectus Department, or by
<FONT STYLE="white-space:nowrap">e-mail</FONT> at </FONT><FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#0000ff"><U>dg.prospectus_requests@baml.com</U></FONT><FONT STYLE="font-family:ARIAL">; or Berenberg Capital Markets LLC, Attention:
Investment Banking, 1251 Avenue of the Americas, 53rd Floor, New York, New York 10020, or by telephone at +1 (646) <FONT STYLE="white-space:nowrap">949-9000,</FONT> or by <FONT STYLE="white-space:nowrap">e-mail</FONT> at </FONT><FONT
STYLE="font-family:ARIAL; font-size:8pt" COLOR="#0000ff"><U><FONT STYLE="white-space:nowrap">prospectusrequests@berenberg-us.com</FONT></U></FONT><FONT STYLE="font-family:ARIAL">. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="justify">This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>About BioNTech </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Biopharmaceutical New Technologies is a next generation
immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="justify">Its broad portfolio of oncology product candidates includes individualized and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> mRNA-based therapies, innovative chimeric antigen receptor T cells, <FONT STYLE="white-space:nowrap">bi-specific</FONT> checkpoint immuno-modulators, targeted
cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and <FONT STYLE="white-space:nowrap">in-house</FONT> manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine
candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech,
a member of the Roche Group, Genevant, Fosun Pharma and Pfizer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><I>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended including, but not
limited to, statements concerning the size and timing of the offerings. In some cases, forward-looking statements can be identified by terminology such as &#147;will,&#148; &#147;may,&#148; &#147;should,&#148; &#147;expects,&#148;
&#147;intends,&#148; &#147;plans,&#148; &#147;aims,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148; &#147;continue,&#148; or the negative of these terms or other comparable
terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements
because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech&#146;s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking
statements. You should review the risks and uncertainties described under the heading &#147;Risk Factors&#148; in BioNTech&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> and those described in BioNTech&#146;s prospectuses
filed with the SEC on July&nbsp;21, 2020 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC&#146;s website at www.sec.gov. Except as required by law, BioNTech disclaims any intention or responsibility for
updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on BioNTech&#146;s current expectations and speak only
as of the date hereof. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>For more information, please contact: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Media Relations: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Jasmina Alatovic, Senior Manager Global External
Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Tel: +49 (0)6131 9084 1513 or +49 (0)151 1978 1385 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><FONT
STYLE="white-space:nowrap">E-mail:</FONT> <FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#0000ff"><U>Media@biontech.de</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Investor Relations: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Sylke Maas, Ph.D., VP Investor Relations&nbsp;&amp;
Business Strategy </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Tel: +49 (0)6131 9084 1074 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">E-mail:</FONT> <FONT STYLE="font-family:ARIAL; font-size:8pt" COLOR="#0000ff"><U>Investors@biontech.de</U></FONT><FONT
STYLE="font-family:ARIAL"> </FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g80965dsp1.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80965dsp1.gif
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MQO__Y[7&QM;>A
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M0+\Y_JR@T+IQMAO*!$<]<+$@3=*X &8X "F) <L) '"&V X2PA=LU2!P(AF
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M)$A%ZH@C;0E:$"V@.IUPO;$\X0B@]-XRX62#O%D*"ASI!$GY.0E_Q@^ERR'
M$B[A_H.HBO21Y_-3QX P A4F0@$ZT!)2)."E,CJ";#V500T0R#UYTI,5"Q@?
M"U[@ DIN8JG6/*D@/+B")"C !H -K& '*UBX^8"0.1# ';-HRT*0H%(5*T #
ME+"$!"0ML$E+@ X0T "M'B4 T<KD69G 5K9LM&T=-<1?"<O:UKK6!GMT)E(&
M$($)Z& $0SC!:ULK&+R:%)M-B4 #ADO<XAKWN!&H5!$FF+_&%@((D+7402*
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34'70MLWM;GO[V^ .M[@3$0@ .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
